The cardio-protective effect of cardiomyopeptidin in critically ill patients with myocardial injury: a retrospective cohort study.
Cardio-protective effect
Cardiomyopeptidin
Mortality
Myocardial injury
Journal
BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539
Informations de publication
Date de publication:
01 Nov 2024
01 Nov 2024
Historique:
received:
13
05
2024
accepted:
21
10
2024
medline:
1
11
2024
pubmed:
1
11
2024
entrez:
1
11
2024
Statut:
epublish
Résumé
In order to investigate the association between the use of cardiomyopeptidin (CMP) and outcomes in critically ill patients with myocardial injury, we conducted a retrospective cohort study in Nanfang hospital, Southern Medical University. Clinical data of patients with myocardial injury were collected retrospectively and adjusted for possible confounders by propensity score weighting. The main outcome was the in-hospital mortality. Secondary outcomes included the major adverse cardiovascular events (MACE) occurring during the hospital, the individual components of MACEs, changes in high sensitive troponin T (hsTnT) levels, length of stay (LOS) in ICU and hospital. A Cox proportional hazards model was constructed to examine the association between the application of CMP and in-hospital mortality. Logistic regression and linear regression are used to analyze secondary outcomes. In total, 339 critically ill patients with myocardial injury were included in the analysis. After inverse probability of treatment weighting (IPTW), the use of CMP was associated with reduced in-hospital mortality (HR: 0.64, 95%CI: 0.43-0.96, P = 0.03). No significant differences were found in change of hsTnT, the occurrence of MACE and LOS in ICU as well as hospital after IPTW. The association was more significant in the subgroup with hsTnT > 3URL (HR: 0.41, 95%CI: 0.23-0.71, P < 0.001) and APACHE II score < 25 (HR: 0.13, 95%CI: 0.17-0.59, P < 0.001). Cardiomyopeptidin was associated with reduced in-hospital mortality in critically ill patients with myocardial injury. Our study provides initial clinical basis for the application of CMP with cardio-protective effect in critically ill patients. These results need to be confirmed in future randomized controlled trails.
Identifiants
pubmed: 39482625
doi: 10.1186/s12872-024-04277-0
pii: 10.1186/s12872-024-04277-0
doi:
Substances chimiques
Biomarkers
0
Troponin T
0
Cardiotonic Agents
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
608Subventions
Organisme : Basic and Applied Basic Research Foundation of Guangdong Province
ID : 2021A1515111028
Organisme : Basic and Applied Basic Research Foundation of Guangdong Province
ID : 2021A1515111028
Organisme : Basic and Applied Basic Research Foundation of Guangdong Province
ID : 2021A1515111028
Organisme : Basic and Applied Basic Research Foundation of Guangdong Province
ID : 2021A1515111028
Organisme : Basic and Applied Basic Research Foundation of Guangdong Province
ID : 2021A1515111028
Organisme : Basic and Applied Basic Research Foundation of Guangdong Province
ID : 2021A1515111028
Organisme : Basic and Applied Basic Research Foundation of Guangdong Province
ID : 2021A1515111028
Organisme : Basic and Applied Basic Research Foundation of Guangdong Province
ID : 2021A1515111028
Informations de copyright
© 2024. The Author(s).
Références
Mensah GA, Roth GA, Fuster V. The Global Burden of Cardiovascular diseases and Risk factors: 2020 and Beyond. J Am Coll Cardiol. 2019;74(20):14–20.
Nadar SK, et al. Characteristics and outcomes of critically ill patients with raised Cardiac Troponins admitted in the Intensive Care Unit: a single centre experience from Oman. Sultan Qaboos Univ Med J. 2022;22(1):37–44.
doi: 10.18295/squmj.4.2021.060
pubmed: 35299794
pmcid: 8904123
Thygesen K, et al. Fourth Universal Definition of Myocardial Infarction (2018). Circulation. 2018;138(20):e618–e651.
doi: 10.1161/CIR.0000000000000617
pubmed: 30571511
John J, et al. Troponin-I as a prognosticator of mortality in severe sepsis patients. J Crit Care. 2010;25(2):270–275.
doi: 10.1016/j.jcrc.2009.12.001
pubmed: 20149590
Devereaux PJ, et al. Association of Postoperative High-Sensitivity troponin levels with myocardial Injury and 30-Day mortality among patients undergoing noncardiac surgery. JAMA. 2017;317(16):1642–1651.
doi: 10.1001/jama.2017.4360
pubmed: 28444280
Yang LP, et al. [Preventive effect of cardiomyopeptidin on rat heart injured by ischemia-reperfusion]. Zhongguo Zhong Yao Za Zhi. 2000;25(2):105–107.
pubmed: 12212070
Yang L, et al. [Effect of cardiomyopeptidin for injection on energy metabolism in isolated hearts of young rats after ischemia-reperfusion injury]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2010;35(6):598–606.
pubmed: 20622333
Yang LP, et al. [Recovery effect of cardiomyopeptidin fractions and fraction addition on cardiac muscle cells in rats damaged by adriamycin]. Zhongguo Zhong Yao Za Zhi. 2000;25(6):362–363.
pubmed: 12512426
van Buuren S. Groothuis-Oudshoorn, mice: multivariate imputation by chained equations in R. J Stat Softw. 2011;45(3):1–67.
doi: 10.18637/jss.v045.i03
Chesnaye NC, et al. An introduction to inverse probability of treatment weighting in observational research. Clin Kidney J. 2022;15(1):14–20.
doi: 10.1093/ckj/sfab158
pubmed: 35035932
Noble JS, et al. Troponin I and myocardial injury in the ICU. Br J Anaesth. 1999;82(1):41–46.
doi: 10.1093/bja/82.1.41
pubmed: 10325834
Quenot JP, et al. Myocardial injury in critically ill patients: relation to increased cardiac troponin I and hospital mortality. Chest. 2005;128(4):2758–2764.
doi: 10.1378/chest.128.4.2758
pubmed: 16236952
Frencken JF, et al. Myocardial Injury in critically ill patients with community-acquired Pneumonia. A cohort study. Ann Am Thorac Soc. 2019;16(5):606–612.
doi: 10.1513/AnnalsATS.201804-286OC
pubmed: 30521759
Frencken JF, et al. Etiology of Myocardial Injury in critically ill patients with Sepsis: a Cohort Study. Ann Am Thorac Soc. 2022;19(5):773–780.
doi: 10.1513/AnnalsATS.202106-689OC
pubmed: 34784496
Frencken JF, et al. Myocardial Injury in patients with Sepsis and its Association with Long-Term Outcome. Circ Cardiovasc Qual Outcomes. 2018;11(2):e004040.
doi: 10.1161/CIRCOUTCOMES.117.004040
pubmed: 29378734
Pölzl L, et al. Association of High-Sensitivity Cardiac Troponin T with 30-Day and 5-Year mortality after cardiac surgery. J Am Coll Cardiol. 2023;82(13):1301–1312.
doi: 10.1016/j.jacc.2023.07.011
pubmed: 37730286
Sessler DI, Khanna AK. Perioperative myocardial injury and the contribution of hypotension. Intensive Care Med. 2018;44(6):811–822.
doi: 10.1007/s00134-018-5224-7
pubmed: 29868971
Chew MS, et al. Identification of myocardial injury using perioperative troponin surveillance in major noncardiac surgery and net benefit over the revised Cardiac Risk Index. Br J Anaesth. 2022;128(1):26–36.
doi: 10.1016/j.bja.2021.10.006
pubmed: 34857357
Stroda A et al. Myocardial Injury Is Associated with the Incidence of Major Adverse Cardiac Events in Patients with Severe Trauma. J Clin Med, 2022. 11(24).
Sun T, et al. Efficacy of Levosimendan in the treatment of patients with severe septic cardiomyopathy. J Cardiothorac Vasc Anesth. 2023;37(3):344–349.
doi: 10.1053/j.jvca.2022.10.032
pubmed: 36473763
Rysz S et al. The Use of Levosimendan after Out-of-hospital cardiac arrest and its Association with Outcome-An Observational Study. J Clin Med, 2022. 11(9).
Le S, et al. Continuous administration of recombinant human B-type natriuretic peptide can improve heart and renal function in patients after cardiopulmonary bypass surgery. J Thorac Dis. 2017;9(3):692–701.
doi: 10.21037/jtd.2017.03.20
pubmed: 28449477
pmcid: 5394037